The Hiring Mistake Surgical Robotics Companies Keep Making
Good technology rarely fails on its own. In surgical robotics, it often stalls when companies hire for scale before they have earned the right to scale.
The surgical robotics market is not short of impressive technology.
It is short of companies that know exactly when that technology is ready to be scaled commercially.
Most founders building in this space understand that commercial execution will define the next phase of the market. Fewer have worked out that commercial execution starts well before the first sales hire, and that getting the sequence wrong is one of the most expensive mistakes a surgical robotics company can make.
The Problem is Timing
In one recent conversation, a founder described the need as “a VP Sales who can open the US.” After twenty minutes, it was clear they had not yet decided which first indication they were prepared to prioritise, who would own surgeon training, or what evidence the first hospital system would need to approve the platform. That is not a VP Sales brief. That is a commercial readiness problem.
It is also a remarkably common one.
Many companies bring in commercial leadership before they have defined what commercial readiness actually means for their specific platform, at their specific stage, in their specific clinical context. If nobody has worked out what a hospital’s value analysis committee needs to approve, or how surgeon training will be staffed beyond the first ten cases, a heavyweight hire does not fix those problems. It makes the organisation noisier. More meetings. More pipeline. More logos in the deck.
When those foundations are absent, the hire pressurises the business rather than accelerates it. The commercial leader is incentivised to generate activity. The organisation starts chasing opportunities it is not ready to close. Surgeon enthusiasm gets mistaken for hospital buying intent. Logos accumulate. Utilisation does not.
This is not a hypothetical failure mode. It is a pattern.
What Poor Sequencing Looks Like in Practice
Asensus Surgical is a useful cautionary example. The company received FDA clearance for the Senhance system in 2017. It had genuine technology, genuine clinical interest, and genuine ambition to challenge Intuitive Surgical in the soft-tissue space. Senhance recorded more than 3,550 procedures in 2023 and won an expanded urology indication as late as July 2024. The technology worked. Surgeons used it.
By early 2024, the company was generating approximately $1.1 million in quarterly revenue against a net loss of $22.5 million, with around $8 million in cash remaining. Karl Storz completed the acquisition in August 2024.
From the outside, Asensus looks less like a failure of surgical robotics technology and more like a reminder that clinical progress and commercial durability are not the same thing. The unresolved questions appeared to be which hospitals, in which order, for which procedures, under which economic model, and with what kind of field support. Regulatory momentum and procedure activity could not substitute for answers to those questions. Without them, a commercial organisation has nothing concrete to execute against.
That is what unresolved sequencing looks like from the outside.
What Good Sequencing Looks Like
CMR Surgical offers the clearest contrast.
After receiving FDA marketing authorisation for Versius in October 2024, CMR did not treat US entry as a simple hiring exercise. CEO Massimiliano Colella had already made the deliberate decision to delay the initial US launch, waiting for the more advanced Versius Plus platform rather than risk a stumble in the world’s largest robotic surgery market. His reasoning was explicit: “It’s a market where we cannot afford a single mistake.”
By the time CMR appointed Chris O’Hara as Commercial President and General Manager for the US in August 2025, the company had secured over $200 million in financing for US market entry, accumulated more than 36,000 procedures globally across 30 countries, and created a much clearer platform for commercial expansion. Versius Plus clearance followed in December 2025, strengthening that position further. O’Hara joined a company with regulatory authorisation, meaningful procedure experience, fresh capital, and a defined market entry mandate.
Distalmotion followed a similarly disciplined path. The company received De Novo authorisation for its DEXTER system in October 2024 for adult inguinal hernia repair, after more than 1,300 patients had already been treated in Europe. It moved into first US outpatient cases in December 2024, recorded its first US sale in March 2025, and raised $150 million in November 2025 specifically to accelerate US adoption, with a stated ambulatory surgery centre focus and a defined commercial wedge already visible in practice. The company knew its first indication, its first site of care, and its first customer profile before pushing harder on scale.
Moon Surgical followed a similar logic, though at an earlier stage. After building limited-release traction with the Maestro system across more than 1,600 procedures and 60 procedure types, the company expanded its US sales and marketing leadership with hires from Intuitive Surgical and ConMed. The expansion was designed to build on visible early traction, not to generate it from scratch.
The Stage Matching Problem
One reason sequencing goes wrong is that founders assume one type of commercial leader can navigate all stages of a platform launch. The skills required to open a category are different from the skills required to build a market. Securing first reference sites requires different judgement from converting surgeon enthusiasm into institutional adoption. A strong capital sales operator hired into an early adoption phase may close impressive early.
accounts but leave no repeatable process behind. A market development leader hired into a scaling phase may be too deliberate for the pace the business now requires.
Wrong-stage hires in surgical robotics are expensive. Not just in direct cost, but in the strategic confusion they generate, the expectations they set with boards and investors, and the time lost realigning when the model fails to convert.
Candidates Know This Now
The other significant shift is happening on the candidate side.
The best commercial leaders in surgical robotics are no longer simply evaluating the platform. They are diligence-testing the company. Before they agree to join, they want to understand regulatory status, clinical evidence strength, manufacturing reliability, reimbursement logic, training model, indication focus, and whether the board and CEO have a realistic view of the adoption timeline.
Strong candidates have seen what happens when those foundations are not in place. They have learned to distinguish between a difficult commercial challenge and an incoherent one. A difficult challenge has a clear clinical use case, a defined early customer profile, and a realistic path to repeatable adoption. An incoherent challenge has ambition in place of answers.
The quality of your sequencing thinking will determine the quality of the candidates you can attract. A company that has done the hard work of defining what commercial readiness means for its platform will attract stronger leaders, at better terms, with more realistic expectations on both sides. A company that has not will attract people comfortable with ambiguity, but not necessarily people skilled at reducing it.
The Inflection Point
Surgical robotics is entering its most commercially scrutinised phase. Multiple platforms are now cleared. Capital is available selectively, flowing to companies with evidence, a coherent regulatory path, and a credible market entry narrative. Intuitive has noted publicly that more customer choice may lengthen capital selling cycles as hospitals take longer to evaluate alternatives.
As more platforms compete for the same hospital budgets, the same surgical time, and the same commercial talent, the companies that have done the foundational thinking will separate from those that have not.
The technology race got surgical robotics here.
Commercial sequencing will decide who scales.
